Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Final Risk-Benefit Guidance Excludes 510(k)s, Adds De Novo Petitions

This article was originally published in The Gray Sheet

Executive Summary

Device center reviewers will begin applying the guidance to incoming PMA and de novo submissions and to submissions already under review with decisions beginning on May 1.

You may also be interested in...

Benefit-Risk Calls On PMAs Based On Patient Pluses Versus Adverse-Event Chances, Guidance Says

In an Aug. 24 guidance, US FDA says it's swayed by what it and patients believe are the magnitude and duration of benefits of a device or diagnostic, versus how troublesome any adverse events might be, and patient tolerance for them. The document describes factors the agency relies on when making risk-benefit decisions about PMA submissions and de novo classifications. Further, the agency expects sponsors and staff to recalculate the benefits and risks at every step along the device development process – and beyond.

Device Consortium Tries To Shed Light on Patient Risk-Benefit Preferences

The public-private Medical Device Innovation Consortium issued a report outlining strategies for incorporating patient preference data into device applications.

Companion Diagnostics For Breakthrough Drugs Also Getting Swift Attention, FDA Says

Device center officials cite a host of formal and informal actions available under existing legislative authority to ensure that development and review of companion diagnostics do not hinder the ability of FDA-designated breakthrough drugs from coming to market.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts